Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: A randomized controlled trial

British Journal of Dermatology

Volumn 154, Issue 6, 2006, Pages 1161-1168

  Reich, K ^a   Nestle, F O ^b   Papp, K ^c   Ortonne, J P ^d   Wu, Y ^e   Bala, M ^e   Evans, R ^e   Guzzo, C ^e   Li, S ^e   Dooley, L T ^e   Griffiths, C E M ^f  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c PROBITY MEDICAL RESEARCH   (Canada)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^e CENTOCOR INC   (United States)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Dermatology Life Quality Index; Infliximab; Psoriasis; Quality of life; Randomized controlled trial; Tumour necrosis factor

Indexed keywords

INFLIXIMAB; PLACEBO;

ADULT; ARTICLE; CHRONIC DISEASE; CHRONIC PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEALTH SURVEY; HIGH RISK PATIENT; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSORIASIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36; SOCIAL INTERACTION;

ADULT; ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; PSYCHOMETRICS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33646547957     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2006.07237.x     Document Type: Article

References (31)

1. Mukhtar R Choi J Koo JY Quality of life issues in psoriasis Dermatol Clin 2004 22 389 95
2. Rapp SR Feldman SR Exum ML et al. Psoriasis causes as much disability as other major medical diseases J Am Acad Dermatol 1999 41 401 7
3. Zachariae R Zachariae C Ibsen HH et al. Psychological symptoms and quality of life of dermatology outpatients and hospitalised dermatology patients Acta Derm Venereol (Stockh) 2004 84 205 12
4. Fortune DG Main CJ O'Sullivan TM Griffiths CEM Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress Br J Dermatol 1997 137 755 60
5. Niemeier V Winckelsesser T Gieler U Skin disease and sexuality. An empirical study of sex behavior of patients with psoriasis vulgaris and neurodermatitis in comparison with skin-healthy probands Hautarzt 1997 48 629 33
6. Gupta MA Gupta AK Psoriasis and sex: a study of moderately to severely affected patients Int J Dermatol 1997 36 259 62
7. Koo J Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment Dermatol Clin 1996 14 485 96
8. Stern RS Nijsten T Feldman SR et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction J Investig Dermatol Symp Proc 2004 9 136 9
9. Krueger G Koo J Lebwohl M et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey Arch Dermatol 2001 137 280 4
10. Rapp SR Exum ML Reboussin DM et al. The physical, psychological and social impact of psoriasis J Health Psychol 1997 2 525 37
11. Lundberg L Johannesson M Silverdahl M et al. Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity Acta Derm Venereol (Stockh) 2000 80 430 4
12. Wahl A Loge JH Wiklund I Hanestad BR The burden of psoriasis: a study concerning health-related quality of life among Norwegian adult patients with psoriasis compared with general population norms J Am Acad Dermatol 2000 43 803 8
13. Finlay AY Khan GK Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use Clin Exp Dermatol 1994 19 210 16
14. Ware JE Jr. Sherbourne CD The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection Med Care 1992 30 473 83
15. Kupper TS Immunologic targets in psoriasis N Engl J Med 2003 349 1987 90
16. Nickoloff BJ Nestle FO Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities J Clin Invest 2004 113 1664 75
17. Sterry W Barker J Boehncke WH et al. Biological therapies in the systemic management of psoriasis: International Consensus Conference Br J Dermatol 2004 151 3 17
18. Boyman O Hefti HP Conrad C et al. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha J Exp Med 2004 199 731 6
19. Chaudhari U Romano P Mulcahy LD et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial Lancet 2001 357 1842 7
20. Gottlieb AB Evans R Li S et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomised, double-blind, placebo-controlled trial J Am Acad Dermatol 2004 51 534 42
21. Reich K Nestle FO Ortonne J-P et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial Lancet 2005 366 1367 74
22. Feldman SR Gordon KB Bala M et al. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial Br J Dermatol 2005 152 954 60
23. Fredriksson T Pettersson U Severe psoriasis - oral therapy with a new retinoid Dermatologica 1978 157 238 44
24. Kimball AB Krueger GG Woolley JM Minimal important differences for the Dermatology Life Quality Index (DLQI) in psoriasis patients In American Academy of Dermatology Summer Meeting Program 28 July-1 August 2004 New York Abstract no P98
25. Hongbo Y Thomas CL Harrison MA et al. Translating the science of quality of life into practice: what do Dermatology Life Quality Index scores mean J Invest Dermatol 2005 125 659 64
26. Ware JE Kosinski M Keller SD SF-36 Physical and Mental Summary Scales: a User's Manual Boston, MA New England Medical Center, The Health Institute 1994
27. Ware JE Kosinski M Gandek B SF-36 Health Survey Manual and Interpretation Guide Lincoln, RI QualityMetric Inc. 1993, 2000
28. Samsa G Edelman D Rothman ML et al. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II Pharmacoeconomics 1999 15 141 55
29. Alonso J Ferrer M Gandek B et al. Health-related quality of life associated with chronic conditions in eight countries: results from the International Quality of Life Assessment (IQOLA) Project Qual Life Res 2004 13 283 98
30. Ellis CN Mordin MM Adler EY Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial Am J Clin Dermatol 2003 4 131 9
31. Krueger GG Langley RG Finlay AY et al. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial Br J Dermatol 2005 153 1192 9